Kinneret has over 25 years of experience in senior leadership positions in the biopharmaceutical industry, including vast experience in different aspects of drug discovery and development, deal making and fund-raising.
Kinneret is a Director and Chairperson of the board of directors at a variety of biotech companies, and held director or chairperson position in a number of companies and organizations including Compugen Ltd. (NASDAQ:CGEN) , KAHR Medical, DreaMed Diabetes, Biomica, Nutritional Growth Solutions (NGS. AU), Hadasit, Ramot, Tel Aviv University’s tech transfer arm and FutuRx and its portfolio companies.
Prior to joining FutuRx, Kinneret served as the CEO of BioLineRx, a biopharmaceutical company focused on oncology, where she previously served as General Manager of BioLine Innovations Jerusalem, a biotech incubator wholly-owned by BioLineRx and Vice President of Drug Development at BioLineRx. Before BioLineRx, Kinneret held the position of Vice President of Biology of Compugen Ltd., cancer immunotherapy company and a leader in predictive target discovery. Dr. Livnat-Savitzky holds a PhD with distinction in Human Genetics from the Tel-Aviv University, a Master’s degree in human genetics from Tel Aviv University and B.Sc. in Biology from The Hebrew University of Jerusalem.